ArticleJournal of the Royal Society, Interface2012
Alzheimer's disease: rapid and slow progression.
Article in Journal of the Royal Society, Interface, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Health-related quality of life in people with predementia Alzheimer's disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review.Alzheimer's research & therapy · 2020Pooled it
- Identifying sex-specific sub-phenotypes of Alzheimer's disease progression using longitudinal electronic health records.EBioMedicine · 2026Article
- Genetic Associations with Temporal Modeling of Alzheimer's Disease Progression Supports a Novel Paradigm for Disease Risk.medRxiv : the preprint server for health sciences · 2026Article
- A distinct tau oligomer strain defines the molecular and proteomic landscape of rapidly progressive Alzheimer's disease.Acta neuropathologica · 2026Article
- Directional drift in biologically meaningful vector planes: A proposed geometric framework for early detection of subthreshold disease.PloS one · 2026Article
- Neocortical tau propagation is a mediator of clinical heterogeneity in Alzheimer's disease.Molecular psychiatry · 2025Article
- Identifying Sex-Specific Sub-phenotypes of Alzheimer's Disease Progression Using Longitudinal Electronic Health Records.medRxiv : the preprint server for health sciences · 2025Article
- Fast Declining Prediction in Alzheimer's Disease from Early Clinical Assessment.Current neuropharmacology · 2025Observational
- Adaptive Subtype and Stage Inference for Alzheimer's Disease.Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention · 2024Article
- Deep learning to predict rapid progression of Alzheimer's disease from pooled clinical trials: A retrospective study.PLOS digital health · 2024Article
- Article
- MicroRNA super-resolution imaging in blood for Alzheimer's disease.BMB reports · 2023Article
- Potential Applications of Artificial Intelligence in Clinical Trials for Alzheimer's Disease.Life (Basel, Switzerland) · 2022Review
- Model-based stratification of progression along the Alzheimer disease continuum highlights the centrality of biomarker synergies.Alzheimer's research & therapy · 2022Article
- Machine Learning Approach Predicts Probability of Time to Stage-Specific Conversion of Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2022Article
- Cerebrospinal Fluid Mitochondrial DNA in Rapid and Slow Progressive Forms of Alzheimer's Disease.International journal of molecular sciences · 2020Article
- Fulminant corticobasal degeneration: a distinct variant with predominant neuronal tau aggregates.Acta neuropathologica · 2020Article
- Leverage Real-world Longitudinal Data in Large Clinical Research Networks for Alzheimer's Disease and Related Dementia (ADRD).AMIA ... Annual Symposium proceedings. AMIA Symposium · 2020Article
- First-in-Rat Study of Human Alzheimer's Disease Tau Propagation.Molecular neurobiology · 2019Article
- Cloud-Based Brain Magnetic Resonance Image Segmentation and Parcellation System for Individualized Prediction of Cognitive Worsening.Journal of healthcare engineering · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The variability in the progression of Alzheimer's disease (AD) across patients has made identification of disease-delaying treatments difficult. Quantitative analysis of this variability has important implications in understanding the pathophysiology of AD and identifying disease-delaying treatments. The functional assessment staging (FAST) procedure characterizes seven stages in the course of AD from normal ageing to severe dementia. The present study applied statistical methods to analyse FAST stage durations from a dataset of 648 AD patients. These methods uncovered two distinct types of disease progression, characterized by different mean progression rates. We identified two separate distributions of FAST stage progression times differing by up to 2 years in mean duration within each stage. These results further indicate that if a patient progresses rapidly through a given FAST stage, then their further progression is also likely to be rapid. These findings support the hypothesis that progression of AD can occur via two different pathophysiological mechanisms that lead to distinct average rates of decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.